Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Aged
Biomarkers, Tumor
/ analysis
CD4-CD8 Ratio
CD8-Positive T-Lymphocytes
/ drug effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Follow-Up Studies
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Pleural Effusion, Malignant
/ drug therapy
Prognosis
Retrospective Studies
Survival Rate
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 04 2021
30 04 2021
Historique:
received:
11
01
2021
accepted:
19
04
2021
entrez:
1
5
2021
pubmed:
2
5
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; type 2, slow and indolent; and type 3, with disease progression. CD4/CD8 ratio of 1.93 was selected as the cutoff threshold to predict survival. Most patients of types 1 and 2 effusions possessed pleural effusion with CD4/CD8 ratios ≥ 1.93. The median OS time in type 1, 2, and 3 patients were not reached, 24.8, and 2.6 months, respectively. The median PFS time in type 1, 2, and 3 patients were 35.5, 30.2, and 1.4 months, respectively. The median OS for the group with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were not reached and 2.6 months. The median PFS of those with pleural effusion CD4/CD8 ≥ 1.93 and < 1.93 were 18.4 and 1.2 months. In conclusion, patients with type 1 and 2 effusion patterns had better survival than those with type 3. Type 1 might be interpreted as pseudoprogression of malignant pleural effusion. CD4/CD8 ratio ≥ 1.93 in pleural effusion is a good predicting factor for PFS.
Identifiants
pubmed: 33931705
doi: 10.1038/s41598-021-89043-4
pii: 10.1038/s41598-021-89043-4
pmc: PMC8087817
doi:
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9381Références
BMC Cancer. 2013 Jul 02;13:324
pubmed: 23816056
Clin Cancer Res. 2016 Aug 1;22(15):3924-36
pubmed: 26957562
Eur J Cancer. 2020 Jul;134:19-28
pubmed: 32454395
Thorac Cancer. 2019 Apr;10(4):815-822
pubmed: 30762312
Sci Rep. 2019 Feb 28;9(1):2996
pubmed: 30816121
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
J Thorac Oncol. 2019 Mar;14(3):328-331
pubmed: 30782378
Clin Cancer Res. 2017 Aug 15;23(16):4671-4679
pubmed: 28592629
Clinics (Sao Paulo). 2008 Oct;63(5):637-44
pubmed: 18925324
Br J Cancer. 2019 Jan;120(1):63-68
pubmed: 30377338
PLoS One. 2015 Mar 19;10(3):e0120852
pubmed: 25789627
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563
pubmed: 30409824
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Immunother Cancer. 2019 Oct 18;7(1):266
pubmed: 31627742
J Clin Oncol. 1998 Oct;16(10):3426-32
pubmed: 9779722
Eur J Cancer. 2018 Sep;101:201-209
pubmed: 30077125
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Front Immunol. 2019 Sep 26;10:2254
pubmed: 31616428
J Immunother Cancer. 2016 Nov 15;4:80
pubmed: 27895919
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Thorac Oncol. 2019 Mar;14(3):468-474
pubmed: 30468872
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Thorac Cancer. 2020 Apr;11(4):835-839
pubmed: 32043828